glp 1 patents How to Survive the GLP-1 Patent War: A Strategic Manual for 503B Outsourcing Facilities Lilly patents new GLP-1R agonists

Rubino, D.M., Greenway, F.L., Khalid, U., ONeil, P.M., Rosenstock, J., Rubio, M.A., and Wadden, T.A., 2022

Buyers who want to evaluate supplement options while that equation is still favorable are better positioned to do that now than after the prescription landscape reshapes the category further

Tirzepatide users were less likely to experience any major cardiovascular problems following surgery than people not on the drug (roughly 30% lower risk), though the rate of some problems like heart attacks remained roughly the same between the two groups

However, these animal findings are concerning enough that drug manufacturers and regulatory agencies have recommended caution until we have better human data

older adults with type 2 diabetes: a target trial emulation study